Audit: QRS - Muira Puama for Health & Longevity
Audit conducted on 13/10/2026 19:20 using AI4L + evidence-mcp / Muse 1.0
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 87 |
| Failed | 0 |
| N/A | 7 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All QRS spans traced to ER passages: Protocol (ER 236-241), Benefits (ER 125-149), Risks (ER 175-189), Interactions/Contraindications (ER 205-217), Monitoring (ER 287-296). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious phrasing retained: ‘No comparison … exists for muira puama alone’ (QRS 472 = ER 241), ‘onset for muira puama alone is unknown’ (QRS 500 = ER 270), ‘(theoretical)’ (QRS 548-554 = ER 205-211). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; avoid-populations stay contraindications (QRS 538-540 = ER 213-217) and timing retains ‘in practice’ (QRS 461 = ER 239). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No relabeling: ER Benefit-/Risk-Modifying Factors (ER 152-199) are not surfaced as cautions or side effects in the QRS. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, NCT identifiers, expert names, or brand names in the QRS; all drug names come from ER 205-211 for the same facts. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions or citations appear anywhere in the QRS body. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Tone matches the ER’s cautious framing (e.g., ‘remain unproven in people’, QRS 433 = ER 309). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert yet accessible and objective throughout, with evidence strength stated rather than implied. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence and protocol data without issuing directives to any reader. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advice language; footer states ‘Not medical advice’ (QRS 639). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is presented as labeled information (labels/values/lists); no ‘recommend’ or ‘advise’ wording. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person or ‘the reader’ address anywhere in the visible text. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language in summary areas; technical names are limited to ER drug/class names in the gates, with plain-language parentheticals preserved from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | All content is condensed into single-sheet cells and short list items. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Checked again with 2.6: no direct address in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing (protocol, monitoring cadence, questionnaires) targets proactive health- and longevity-oriented adults, matching ER Motivation (ER 37). |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to follow protocol and monitoring effort (QRS 615, 623-632). |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No general-population framing or population-level thresholds are used; success is framed against individual baseline (QRS 594). |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting reflects this audience: unproven benefits stated plainly alongside monitoring (QRS 433, 578-617). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Uses ‘Longevity’ framing (QRS 22, 417); ‘anti-aging’ does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal terminology used (‘oral botanical supplement’, QRS 433; ‘Oral administration’, QRS 461); no colloquial route/effect terms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” Gate headings: “Contraindications”, “Key Interactions” Tier labels: “High”, “Medium”, “Low”, “Speculative” Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Headings verified at QRS 440, 477, 519, 564, 579, 621; gate headings at QRS 535, 545; tier labels and Monitoring column headers unchanged. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Script comparison against core/qrs/QRS.html: every template span present; template pattern spans marker_#* and qualitative_item# are instantiated as marker_1/2_* and qualitative_item_1-3. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows changes only inside addressed spans and the metadata block; CSS and structure unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | N/A — no QRS section is sourced from an empty ER section; empty benefit/risk tiers are handled under 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Bold ER labels used verbatim: ‘Concentrated extract dose’, ‘Best time of day’, ‘Single versus split doses’ (ER 236-241) and the interaction labels (ER 205-211). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No paraphrased, abbreviated, or invented labels found in protocol, gates, or monitoring rows. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the QRS source. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Template one-page layout retained with condensed per-section content; no sections added or extended (source audit per QRS.md). |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is the first element after <!doctype html> (QRS 1-2). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by ‘—’ lines (QRS 3 and 13). |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Metadata sits inside an HTML comment and is not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; the only quoted value, duration ‘00:03’, contains a colon (QRS 4-12). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename stated at QRS 4. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.10.8 (QRS 5) matches QRS.md line 1. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-1013-1915 in required format (QRS 6). |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname stated at QRS 7. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Nickname ‘Muse’ is a single word without version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname stated at QRS 8. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | ‘Muse 1.0’ gives the model name plus version with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename at QRS 9 matches the audited filename. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-checked with 5.4: all frontmatter values trimmed, quoting only where a colon requires it. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Page title (QRS 22) is the ER canonical_topic (ER 8) plus ‘ - Quick Reference Sheet’, with & encoded as &. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic (QRS 417) equals the ER canonical_topic with & encoding. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date 10/13/2026 (QRS 421) is qrs_creation_date 2026-1013-1915 reformatted as MM/DD/YYYY. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model (QRS 425) equals qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the template title and subline (QRS 415-428); no badges, AKA line, or audit stamps. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with kind and use: ‘oral botanical supplement prepared from the root and bark … used in connection with sexual vitality, mental sharpness, energy, and mood’ (QRS 433) before the evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Dense summary of the ER Conclusion (ER 309): thin combined-product human evidence, unproven healthy-aging benefits, mild digestive/headache complaints. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 58 words (script-counted), within the 70-word limit. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact is supported in ER 37 and ER 309. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; plain terms only. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks, or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER Key Interactions & Contraindications (ER 201-217). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | stop_items reproduce the ER ‘Populations who should avoid Muira Puama’ list (ER 213-217). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Individual items formatted as <li></li> (QRS 538-540). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Items carry only the key fact; ER ‘because …’ explanations and the NCT attribution are stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The ER avoid-population bullets contain no parenthetical time/severity/threshold qualifiers requiring preservation (ER 215-217). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — ER Key Interactions & Contraindications bullets (ER lines 205-217) use no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section is populated because the ER identifies populations who should avoid the intervention (ER 213-217). |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — section is not empty (QRS lines 538-540). |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER Key Interactions & Contraindications (ER 201-211). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | caution_items reproduce all seven ER key interactions (ER 205-211) and none of the contraindication populations. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Individual items formatted as <li></li> (QRS 548-554). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Only the bold label plus ‘Caution/Monitor (theoretical)’ is kept; all ER em-dash rationale clauses are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Parenthetical example-drug lists and ‘(theoretical)’ qualifiers preserved for every item (QRS 548-554 = ER 205-211). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — ER interaction bullets (ER lines 205-211) use no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section is populated because the ER identifies interactions that change use (ER 205-211). |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — section is not empty (QRS lines 548-554). |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (ER 232-247). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Covers dose, time of day, and single versus split dosing (ER 236, 239, 241), the central implementation aspects for a single-ingredient product. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — ER Protocol names three or more actionable aspects (ER lines 236-241). |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All action_1-3 label/value/sub spans are filled with ER-derived content (QRS 442-474). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Time sets cover the two ER time-to-effect aspects (ER 270; benefit sections ER 125-135). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered as in the ER benefit sections (women, ER 125-129, before men, ER 131-135), both at the Low tier. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | Only two distinct aspects exist in the ER; time_3 spans are empty with style=’display:none’ (QRS 503-513). |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All time_1-2 label/value/sub spans are filled with ER-derived content (QRS 481-502). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | N/A — ER provides time-to-effect information (ER line 270). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from ER Expected Benefits (ER 111-150). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | benefits_high/medium/low/speculative spans all present (QRS 521-528). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER benefit headings only (ER 125, 131, 139, 143, 147), with no explanations, effect sizes, or citations. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content carried over; ER magnitudes (ER 129, 135) are omitted. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high and benefits_medium are empty with display:none (QRS 521-522), matching ‘No benefit reaches High/Medium’ (ER 117-121). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from ER Potential Risks & Side Effects (ER 161-190). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | risks_high/medium/low/speculative spans all present (QRS 566-573). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER risk headings only (ER 175, 183, 187), with no frequencies, citations, or added explanations. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content carried over; the ER magnitude (ER 179) is omitted. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium are empty with display:none (QRS 566-567), matching ‘No risk reaches High/Medium’ (ER 167-171). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER 285-292). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | Both measurable biomarkers from the ER monitoring table are listed: Blood pressure and Resting pulse (ER 291-292). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | monitoring_cadence populated from ER 287 (baseline; repeats at 2 weeks, 1 month, then every 1-3 months) at QRS 615. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the same ER Monitoring section (ER 285-296). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All three subjective/qualitative ER items are listed verbatim (QRS 623-632 = ER 294-296). |
Issues 13/10/2026 19:20
Pass rate 100.00%. No issues found.